2. UroToday Home
  3. Urinary Catheters
  4. Indwelling Catheters
  5. Complications
  6. Library Resources

ESMO 2024 Quick Takes Library Resources

ESMO 2024 Quick Takes Library Resources

ESMO 2024 Quick Take Insights: Prostate Cancer

Introduction

At the ESMO 2024 annual meeting in Barcelona, Spain, the results of numerous practice-changing trials were presented, including those from three highly-anticipated clinical trials in the advanced prostate cancer space:

Written by: Zachary Klaassen, MD, MSc, Wellstar MCG Health, Augusta, GA and Rashid Sayyid, MD, MSc, University of Southern California, Los Angeles, CA 
References:
  1. Smith MR, Hussain M, Saad F, et al. Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. N Engl J Med. 2022; 386(12):1132-1142.
  2. Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013; 368(2):138-148.
  3. Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014; 371(5):424-433.
  4. Smith M, Parker C, Saad F, et al. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): A randomized, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019; 20(3):408-419.
  5. Sartor O, de Bono J, Chi KN et al. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2021; 385(12):1091-1103.

ESMO 2024 Quick Take Insights: A Focus on PEACE-3

ESMO 2024 Quick Take Insights: A Focus on PEACE-3

The ESMO 2024 annual meeting in Barcelona, Spain, featured many practice-changing trials and hypothesis-generating data in genitourinary cancer. One of the most highly anticipated trials in the metastatic castration-resistant prostate cancer (mCRPC) disease space was the phase III PEACE-3 trial – the focus of this ESMO 2024 Quick Take Insights.

Written by: Zachary Klaassen, MD, MSc Wellstar MCG Health, Augusta, GA & Rashid Sayyid, MD, MSc, University of Southern California, Los Angeles, CA
References:
  1. Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013; 368(2):138-148.
  2. Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014; 371(5):424-433.
  3. Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013;369(3):213-223.
  4. Rahbar K, Essler M, Pabst KM, et al. Safety and Survival Outcomes of 177Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with Prior 223Ra Treatment: The RALU Study. J Nucl Med. 2023 Apr;64(4):574-578.
  5. Smith M, Parker C, Saad F, et al. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): A randomized, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019; 20(3):408-419.

ESMO 2024 Quick Take Insights: A Focus on ARANOTE

The ESMO 2024 annual meeting in Barcelona, Spain, featured many practice changing trials and hypothesis generating data in genitourinary cancer. One of the most highly anticipated trials in the metastatic hormone sensitive prostate cancer (mHSPC) disease space was the phase III ARANOTE trial – the focus of this ESMO 2024 Quick Take Insights.
Written by: Zachary Klaassen, MD, MSc Wellstar MCG Health, Augusta, GA & Rashid Sayyid, MD, MSc, University of Southern California, Los Angeles, CA
References:
  1. Smith MR, Hussain M, Saad F, et al. Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. N Engl J Med. 2022; 386(12):1132-1142.
  2. Armstrong AJ, Szmulewitz RZ, Petrylak DP, et al. ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy with Enzalutamide or Placebo in Men with Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol. 2019 Nov 10;37(32):2974-2986.

ESMO 2024 Quick Take Insights: A Focus on SPLASH

ESMO 2024 Quick Take Insights: A Focus on SPLASH

The ESMO 2024 annual meeting in Barcelona, Spain, featured many practice-changing trials and hypothesis-generating data in genitourinary cancer. One of the most highly anticipated trials in the metastatic castration-resistant prostate cancer (mCRPC) disease space was the phase III SPLASH trial – the focus of this ESMO 2024 Quick Take Insights.

Written by: Zachary Klaassen, MD, MSc Wellstar MCG Health, Augusta, GA & Rashid Sayyid, MD, MSc, University of Southern California, Los Angeles, CA
References:
  1. Sartor O, de Bono J, Chi KN et al. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2021; 385(12):1091-1103.
  2. Morris MJ, Castellano D, Herrmann K, et al. 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naïve patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): A phase 3, randomized, controlled trial. Lancet 2024 Sep 28;404(10459):1227-1239.